Drug Information

Drug General Information
Drug ID
D00YDN
Former ID
DIB014242
Drug Name
CXR-1002
Indication Cancer [ICD9: 140-229; ICD10:C00-C96] Phase 1 [549291]
Company
CXR Biosciences Ltd
Canonical SMILES
C(C(C(C(C(=O)O)(F)F)(F)F)(F)F)(C(C(C(F)(F)F)(F)F)(F)F)(<br />F)F.N
Target and Pathway
Target(s) Proto-oncogene pim-1 Target Info Inhibitor [551578]
KEGG Pathway Jak-STAT signaling pathway
MicroRNAs in cancer
Acute myeloid leukemia
NetPath Pathway IL9 Signaling Pathway
IL5 Signaling Pathway
IL2 Signaling Pathway
TGF_beta_Receptor Signaling Pathway
TCR Signaling Pathway
Pathway Interaction Database GMCSF-mediated signaling events
Validated targets of C-MYC transcriptional activation
Role of Calcineurin-dependent NFAT signaling in lymphocytes
IL5-mediated signaling events
IL3-mediated signaling events
C-MYB transcription factor network
WikiPathways Ectoderm Differentiation
Hematopoietic Stem Cell Differentiation
References
Ref 549291Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034732)
Ref 551578123 Antitumor activity of CXR1002, a novel anti-cancer clinical phase compound that induces ER stress and inhibits PIM kinases: Human tumor xenograft efficacy and in vitro mode of action. EJC Supplements, 2010; 8(7):45-46.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.